Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma

Indian Journal of Ophthalmology

关键词: Amblyopia;    nasolacrimal duct obstruction;    probing;    Duane syndrome;    esotropia;    strabismus;    Bevacizumab;    mitochondrial function;    microvascular endothelial cells;    neurosensory retinal cells;    retinal pigment epithelial cells;    tissue culture;    Clinical donor tissue grading;    death to enucleation time;    death to preservation time;    eye bank specular microscopy;    optimizing donor tissue utilization;    DCR;    endodiathermy bipolar probe;    nasolacrimal duct obstruction;    recanalize;    Age-related macular degeneration;    carotenoids;    cross-sectional studies;    lutein;    Children;    GDx variable corneal compensation;    Indian;    normal;    retinal nerve fiber layer thickness;    Biological amniotic membrane;    5-fluorouracil;    retina;    trabeculectomy;    Clinical features;    complications;    etiology;    retinal vasculitis;    Thailand;    Coloboma of the choroid;    coloboma optic disc;    indo cyanine green angiography;    vascular pattern;    Aphakia;    inadequate capsular support;    pediatric aphakia;    secondary intraocular lens implantation;    steel suture;    trans-scleral fixation;    vanadium steel;    Drug reaction;    drug-induced;    ranibizumab;    subacute cutaneous lupus erythematosus;    Prevalence;    rapid;    rapid assessment of refractive errors;    spectacles use;    uncorrected refractive errors;    visual impairment;    Bitemporal hemianopia;    Traumatic chiasmal syndrome;    visual field;    Phaeohyphomycosis;    pigmented fungi;    subretinal abscess;    subretinal biopsy;    Brimonidine;    combination;    glaucoma;    intraocular pressure;    timolol;   

DOI  :  10.4103/0301-4738.116456

来源: DOAJ

【 摘 要 】

The aim of present study was to compare the efficacy and safety of fixed combination of brimonidine and timolol with individual components used as monotherapy in patients of primary open angle glaucoma. Patients were randomly assigned to receive brimonidine or timolol or brimonidine-timolol fixed combination, with 30 patients in each group. The mean reduction in intraocular pressure in brimonidine, timolol, and brimonidine-timolol group were 4.29 ± 1.97 mm Hg, 4.34 ± 1.21 mm Hg, and 5.54 ± 1.87 mm Hg respectively at 2 weeks and 4.86 ± 1.16 mm Hg, 5.42 ± 1.50 mm Hg, and 7.36 ± 2.58 mm Hg respectively at 6 weeks. When values of mean reduction in intraocular pressure were compared between brimonidine-timolol fixed combination with brimonidine and timolol, it was found to be statistically significant ( P < 0.05) at 2 weeks and highly significant (0.001) at 6 weeks. The overall frequency of adverse effects was similar in all three groups.

【 授权许可】

Unknown